Entries |
Document | Title | Date |
20100273702 | CHIMERICAL PEPTIDIC MOLECULES WITH ANTIVIRAL PROPERTIES AGAINST THE VIRUSES OF THE FLAVIVIRIDAE FAMILY - The present invention is relative to chimerical peptides, whose primary structure holds at least one segment which inhibits the activation of the NS3 protease of a virus from the Flaviviridae family, they also contain a cell penetrating segment and they are capable of inhibiting or attenuate the viral infection. This invention is also relative to pharmaceutical compounds which contain these chimerical peptides for the prevention and/or treatment of the infection caused by a virus of the Flaviviridae family. | 10-28-2010 |
20100279928 | SLDLR IN VIRAL HEPATITIS - The invention relates to the use of the souluble LDL receptor (sLDLR) in viral hepatitis. | 11-04-2010 |
20100286033 | NEW CYCLIC PEPTIDE COMPOUNDS - The present invention relates to a new cyclic peptide compound or a salt thereof, which has anti-hepatitis C virus activities based on inhibitory activity against the RNA replication of hepatitis C virus replicon, to a process for preparation thereof comprising a rearrangement reaction under a mild acidic condition and the following amino acid changing reactions etc., to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of hepatitis C in a human being or an animal. | 11-11-2010 |
20100292138 | Peptide Derived from Hepatitis C Virus - Disclosed is a pharmaceutical composition for the treatment of an HCV-related disease in a patient having HLA-A24 or -A3 supertype, wherein the pharmaceutical composition comprises a peptide having an amino acid sequence represented by the formula: YLLPRRGPRL (SEQ ID NO:1) as an active ingredient. Also disclosed is a composition for use in the detection of the induction of an HLA-A24 or -A3 supertype-restricted cytotoxic T cell in a patient having HLA-A24 or -A3 supertype, wherein the composition comprises a peptide having an amino acid sequence depicted in SEQ ED NO:1 as an active ingredient. | 11-18-2010 |
20100298210 | HCV NS3 Protease Inhibitors - The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use treating or preventing HCV infections. | 11-25-2010 |
20100323953 | MACROCYCLIC HEPATITIS C PROTEASE INHIBITORS - The present invention provides novel macrocyclic compounds that mimic peptide substrates of the hepatitis C viral protease and inhibit the viral protease, more particularly as inhibitors of the NS3 serine protease from hepatitis C virus. Methods for synthesis of the compounds are also provided. The compounds find utility as antiviral agents directed at hepatitis C. The invention further provides methods of employing such inhibitors, alone or in combination with other therapeutic agents, to treat hepatitis C infection in a subject in need of such treatment. | 12-23-2010 |
20100331243 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 12-30-2010 |
20110015122 | HEPATITIS B VIRUS-BINDING POLYPEPTIDES AND METHODS OF USE THEREOF - The present invention provides non-naturally occurring polypeptides that specifically bind hepatitis B virus (HBV) DNA; and polynucleotides encoding the polypeptides. The present invention further provides methods of detecting HBV DNA; methods of detecting a covalently closed circular DNA (cccDNA) form of HBV; and methods for treating HBV infection. | 01-20-2011 |
20110059886 | HCV NS3-NS4A Protease Inhibition - The present invention relates to inhibiting the activity of non-genotype 1 hepatitis C virus (HCV) NS3-NS4A protease activity. More particularly, the invention relates to inhibiting the activity of the protease from HCV genotype-2 or HCV genotype-3. The methods of the invention emply inhibitors that act by interfering with the life cycle of the HCV and are also useful as antiviral agents. The invention further relates to compositions comprising such compounds either for ex vivo use or for administration to a patient suffering from genotype-2 or genotype-3 HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. | 03-10-2011 |
20110071074 | DEUTERATED HEPATITIS C PROTEASE INHIBITORS - A deuterated α-ketoamido steric specific compound of the formula | 03-24-2011 |
20110092415 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 04-21-2011 |
20110178004 | HEPATITIS B VIRUS PRE-S1 DERIVED SYNTHETIC POLYPEPTIDES AND USES THEREOF - The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies. | 07-21-2011 |
20110183895 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS - The present invention discloses the structure, preparation methods and uses of a series of novel polyheterocyclic based compounds (Ia-Ib and IIa-IIb) that are highly effective for inhibiting hepatitis C virus (HCV): | 07-28-2011 |
20110201548 | THERAPEUTIC AGENT FOR ACUTE HEPATITIS OR PROPHYLACTIC/THERAPEUTIC AGENT FOR FULMINANT HEPATITIS - When acute hepatitis progresses to fulminant hepatitis, a large amount of hepatic cells are rapidly broken, and as a result, the prognosis is seriously worsened. Thus, it is important to prognose the progress of acute hepatitis into fulminant hepatitis at an early stage and quickly start an appropriate treatment therefor. Although the prognosis of progress into fulminant hepatitis becomes possible owing to recent advances in test methods and diagnostic techniques, there has been no appropriate prophylactic/therapeutic agent for fulminant hepatitis. The present invention provides a therapeutic agent for acute hepatitis or a prophylactic/therapeutic agent for fulminant hepatitis with little side effect. The problem of the invention was solved by using a composition containing apolipoprotein A-II. | 08-18-2011 |
20110207660 | PHARMACEUTICAL FORMULATIONS OF AN HCV PROTEASE INHIBITOR IN A SOLID MOLECULAR DISPERSION - The present invention provides pharmaceutical formulations of an HCV protease inhibitor in a solid dispersion with an excipient which provided advantageous pharmacokinetic properties for inhibiting or treating HCV infection. In preferred embodiments, the excipient is at least one polymer. The present invention also provides processes for manufacturing such formulations as well as uses of said composition for the manufacture of a medicament for treating or ameliorating one or more symptoms of HCV or disorders associated with HCV in a subject in need thereof using said formulations. | 08-25-2011 |
20110224134 | MACROCYCLIC QUINOXALINE COMPOUNDS AS HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections. | 09-15-2011 |
20110306541 | METHODS FOR TREATING HCV - This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions. | 12-15-2011 |
20120004161 | HOMOGENOUS PREPARATIONS OF IL-28 AND IL-29 - Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity. | 01-05-2012 |
20120010131 | NOVEL CYCLOSPORIN ANALOGUES - The invention relates to the use of cyclic compounds of general formula (I): | 01-12-2012 |
20120077737 | HEPATITIS C INHIBITOR COMPOUNDS - Compounds of the invention, which are macrocyclic peptide analogs containing an acylsulfonamide moiety, maintain good activity against NS3 proteases containing clinically relevant resistance mutations for this class as represented by genotype 1a R155K, genotype 1b D168V and genotype 1a D168V resistance mutations. The compounds of the invention are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection. | 03-29-2012 |
20120077738 | COMPOSITIONS AND METHODS FOR PREDICTING HCV SUSCEPTIBILITY TO ANTIVIRAL AGENTS - Methods for determining the susceptibility of a hepatitis C virus (HCV) in a patient to anti-viral agents, particularly cyclophilin inhibitors such as cyclosporine A, are disclosed. The methods include determining the amino acid sequence within a region of the HCV NS5A protein and comparing the viral amino acid sequence to that of a reference strain, wherein the existence of at least one variant/mutation in the viral genome is indicative that the virus is more or less susceptible to anti-viral agents. Also disclosed are isolated polynucleotide molecules, replicons, and kits that can be used to assay the susceptibility of hepatitis HCV in a patient to anti-viral agents. | 03-29-2012 |
20120083441 | Pharmaceutical Compositions - Forms and formulations of VX-950 and uses thereof. | 04-05-2012 |
20120088718 | HCV-DERIVED POLYPEPTIDES AND USES THEREOF - The present invention relates to Hepatitis C virus (HCV)-derived polypeptides and nucleic acid molecules encoding same which advantageously comprises a cd81-binding region. In this connection, the present invention specifically relates to the use of the polypeptides or nucleic acid molecules in compositions and methods for the prevention, the treatment and the diagnosis of HCV infections. | 04-12-2012 |
20120094897 | NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, and II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 04-19-2012 |
20120101032 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The embodiments provide compounds of the general Formulae I, Ia, II, IIa, III, IIIa, IV, IVa, V, Va, VI and VIa, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition. | 04-26-2012 |
20120129765 | NOVEL SPECIFIC HCV NS3 PROTEASE INHIBITORS - The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts. | 05-24-2012 |
20120172290 | Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 07-05-2012 |
20120172291 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 07-05-2012 |
20120190614 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 07-26-2012 |
20120196794 | Combinations of Hepatitis C Virus Inhibitors - The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating hepatitis C using such combinations. | 08-02-2012 |
20120208746 | GENETIC MARKERS ASSOCIATED WITH RESPONSE TO CYCLOPHILIN-BINDING COMPOUNDS - Methods of predicting the response in a patient infected with hepatitis C virus (HCV) to a treatment regime involving the use of a cyclophilin-binding compound are described which provide for improvements in treatments, pharmaceutical compositions, dosing regimen, assays, kits, and other aspects of the art. | 08-16-2012 |
20120220520 | BIOAVAILABLE COMBINATIONS FOR HCV TREATMENT - The present invention relates to the combination comprising an HCV NS3/4a protease inhibitor and a compound of formula (II). The combination is useful to improve the bioavailability of the HCV NS3/4a protease inhibitor. As such, the combination is useful for treating conditions associated with the Hepatitis C virus in patients. Pharmaceutical compositions and kits comprising this combination, and processes for preparing the combination and the pharmaceutical formulations are also provided. | 08-30-2012 |
20120231998 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases. | 09-13-2012 |
20120252721 | METHODS FOR TREATING DRUG-RESISTANT HEPATITIS C VIRUS INFECTION WITH A 5,5-FUSED ARYLENE OR HETEROARYLENE HEPATITIS C VIRUS INHIBITOR - Provided herein are methods for treating or preventing drug-resistant hepatitis C virus infection in a subject, which comprises administering to the subject a 5,5-fused heteroarylene hepatitis C virus inhibitor compound, for example, of Formula I, IA, or IB. | 10-04-2012 |
20120258909 | Solid Compositions - The present invention features solid compositions comprising amorphous Compound I. For instance, Compound I may be formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant. | 10-11-2012 |
20120264679 | 3-ETHER AND 3-THIOETHER SUBSTITUTED CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF HEPATITIS C INFECTION - This invention relates to cyclosporin derivatives of general formula (I): | 10-18-2012 |
20120270775 | CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR - This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection: | 10-25-2012 |
20120295842 | PHENANTHRIDINE MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 11-22-2012 |
20120295843 | COMBINATION THERAPY FOR THE TREATMENT OF HCV INFECTION - The present invention relates to therapeutic combinations comprising a protease inhibitor and a polymerase inhibitor for the treatment of HCV. The present invention also relates to therapeutic combinations comprising VX-950 and a polymerase inhibitor. Also within the scope of the invention are methods using the therapeutic combinations of the present invention for treating HCV infection or alleviating one or more symptoms thereof in a patient. The present invention also provides kits comprising the combinations of the present invention. | 11-22-2012 |
20120329706 | HEPATITIS B VIRUS PRE-S1 DERIVED SYNTHETIC POLYPEPTIDES AND USES THEREOF - The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies. | 12-27-2012 |
20130012430 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HEPATITIS C VIRUS NS3 PROTEASE - The present invention relates to compounds, methods and pharmaceutical compositions for inhibiting proteases, particularly serine proteases, and more particularly HCV NS3 proteases. The compounds, and the compositions and methods that utilize them, can be used, either alone or in combination to inhibit viruses, particularly HCV virus. | 01-10-2013 |
20130017991 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 01-17-2013 |
20130029904 | HCV COMBINATION THERAPY - Aspects of this invention include methods comprising administering a combination of a Compound (1) below, including particular en crystalline forms thereof and pharmaceutically acceptable salts thereof, with at least one further selected HCV inhibiting compound as described herein for the treatment of Hepatitis C Viral (HCV) infection The methods can be conducted administering the Compound (1) and the at least one further selected HCV inhibiting compound separately or together, including as a regimen of treatment. | 01-31-2013 |
20130102525 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. | 04-25-2013 |
20130102526 | Methods for Treating HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 04-25-2013 |
20130116169 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds. | 05-09-2013 |
20130172239 | SOLID COMPOSITIONS - The present invention features solid compositions comprising a selected HCV inhibitor in an amorphous form. In one embodiment, the selected HCV inhibitor is formulated in an amorphous solid dispersion which comprises a pharmaceutically acceptable hydrophilic polymer and preferably a pharmaceutically acceptable surfactant. | 07-04-2013 |
20130172240 | METHODS FOR TREATING HCV - The present invention features interferon-free therapies for the treatment of HCV. The therapies comprise administering Compound I (or a pharmaceutically acceptable salt thereof) and another anti-HCV agent. Preferably, the therapies are both interferon- and ribavirin-free. | 07-04-2013 |
20130178413 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic compounds of formula I that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. | 07-11-2013 |
20130190229 | VITAMIN E FORMULATIONS OF SULFAMIDE NS3 INHIBITORS - The invention relates to new formulations of compounds having activity against HCV-associated disorders, new combinations, new methods of treatment and their use in therapy. | 07-25-2013 |
20130203656 | INHIBITORS OF HCV NS5A - Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C. | 08-08-2013 |
20130225483 | New Treatments of Hepatitis C Virus Infection - The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus genotype 2 or 3 infection. | 08-29-2013 |
20130261050 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUB-POPULATION - The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient having compensated liver disease. | 10-03-2013 |
20130274179 | VIRAL POLYMERASE INHIBITORS - The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections. | 10-17-2013 |
20130274180 | Pharmaceutical Compositions - Forms and formulations of VX-950 and uses thereof. | 10-17-2013 |
20130281362 | ANTIVIRAL AGENT - The present invention proposes a combination of bis-(gamma-L-glutamyl)-L-cysteinyl-glycine or a salt thereof, inosine and coordination compounds formed by palladium, copper and (gamma-L-glutamyl)-L-cysteinyl-glycine; a pharmaceutical composition and an anti-viral agent based on said combination, and also a method for treatment of a viral disease. | 10-24-2013 |
20130288957 | ORAL COMBINATION THERAPY FOR TREATING HCV INFECTION IN SPECIFIC PATIENT SUBGENOTYPE POPULATIONS - The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) Compound (2), or a pharmaceutically acceptable salt thereof, as herein described, and optionally (c) ribavirin, and methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient that has genetic variations located near the IL28B gene, including SNP rs12979860 with a CC or non-CC genotype and SNP rs8099917 with a TT or non-TT genotype. | 10-31-2013 |
20130303438 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION - The present invention relates to a compound of the formula (I): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing a viral infection using the same. | 11-14-2013 |
20130316945 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds of formula I: | 11-28-2013 |
20130331314 | PHARMACEUTICAL COMPOSITION FOR TREATING HCV INFECTIONS - The present invention relates to a granular pharmaceutical composition comprising an HCV protease inhibitor and at least one poloxamer. | 12-12-2013 |
20130338061 | Salts and Polymorphs of Sulfamide NS3 Inhibitors - The invention provides new salts and polymorphs of (5R,8S)-7-[(2S)-2-{[(2S)-2-cyclohexyl-2-({[(2S)-1-isopropylpiperidin-2-yl]carbonyl}amino)acetyl]amino}-3,3-dimethyl butanoyl]-N-{(1R,2R)-2-ethyl-1-[(pyrrolidin-1-ylsulfonyl)carbamoyl]cyclopropyl}-10,10-dimethyl-7-azadispiro[3.0.4.1]decane-8-carboxamide (referred to herein as Compound X), pharmaceutical compositions containing them and processes for their manufacture and use in therapy. | 12-19-2013 |
20130338062 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 12-19-2013 |
20140005104 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | 01-02-2014 |
20140011736 | TREATMENT FOR INFECTION WITH HEPATITIS B VIRUS ALONE OR IN COMBINATION WITH HEPATITIS DELTA VIRUS AND ASSOCIATED LIVER DISEASES - The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis B and Hepatitis D virus infections. | 01-09-2014 |
20140018289 | New treatments of Hepatitis C virus infection - The disclosure concerns the use of cyclophilin inhibitors in the treatment of chronic Hepatitis C virus infection. | 01-16-2014 |
20140024579 | METHODS FOR TREATING HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. | 01-23-2014 |
20140031277 | INHIBITORS OF SERINE PROTEASES, PARTICULARLY HCV NS3-NS4A PROTEASE - The present invention relates to compounds of formula I: | 01-30-2014 |
20140051626 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 02-20-2014 |
20140057835 | METHODS FOR TREATING HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 02-27-2014 |
20140057836 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds. | 02-27-2014 |
20140107016 | Methods for Treating HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 04-17-2014 |
20140107017 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. | 04-17-2014 |
20140135259 | TREATMENT OF HEPATITIS C VIRUS - A combined therapy which utilizes hydroxychloroquine and GNS-227: | 05-15-2014 |
20140162942 | INHIBITION OF CYP3A DRUG METABOLISM - The present invention provides methods, pharmaceutical compositions, medicaments, and pharmaceutical kits that employ the use of boceprevir as a CYP3A4/5 inhibitor to improve the pharmacokinetics of therapeutic compounds metabolized by cytochrome P450 3A4/5 (CYP3A4/5) enzymes. | 06-12-2014 |
20140179595 | APOLIPOPROTEIN E POLYPEPTIDES AND THEIR USE - Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods | 06-26-2014 |
20140194350 | MACROCYCLIC PROLINE DERIVED HCV SERINE PROTEASE INHIBITORS - The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 07-10-2014 |
20140206604 | 4-AMINO-4-OXOBUTANOYL PEPTIDE CYCLIC ANALOGUES, INHIBITORS OF VIRAL REPLICATION - The invention provides 4-amino-4-oxobutanoyl peptides and cyclic analogues thereof of Formula I | 07-24-2014 |
20140206605 | CRYSTAL FORMS OF A HCV PROTEASE INHIBITOR - The present invention relates to different forms of a HCV inhibitory compound. | 07-24-2014 |
20140221275 | OLIGOPEPTIDE FOR TREATING LIVER FIBROSIS AND/OR TREATING HEPATITIS B AND/OR IMPROVING LIVER FUNCTION - Disclosed is an oligopeptide for treating liver fibrosis and/or hepatitis B and/or improving liver function. The oligopeptide is obtained by reflux extraction via water, ethanol precipitation and isolation through a cation exchange resin column and a gelatinous resin column from a turtle shell. Pharmaceutically conventional excipients can be added to the oligopeptide prepared according to the present invention to prepare various dosage forms. The oligopeptide has good efficacy in treating liver fibrosis and improving liver function. | 08-07-2014 |
20140243257 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS - Compounds represented by formula I: | 08-28-2014 |
20140249074 | ANTIVIRAL COMPOUNDS - The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 09-04-2014 |
20140274884 | INHIBITORS OF HEPATITIS C VIRUS - Compounds of formula I: | 09-18-2014 |
20140287991 | Hepatitis B Virus-Binding Polypeptides and Methods of Use Thereof - The present invention provides non-naturally occurring polypeptides that specifically bind hepatitis B virus (HBV) DNA; and polynucleotides encoding the polypeptides. The present invention further provides methods of detecting HBV DNA; methods of detecting a covalently closed circular DNA (cccDNA) form of HBV; and methods for treating HBV infection. | 09-25-2014 |
20140287992 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 09-25-2014 |
20140296136 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. | 10-02-2014 |
20140309164 | DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV - Deuterated nucleoside analogs of Formula (I) and the pharmaceutically acceptable salts thereof are provided by this disclosure | 10-16-2014 |
20140315792 | ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. | 10-23-2014 |
20140323395 | Methods for Treating HCV - The present invention features interferon- and ribavirin-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration of treatment, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents without interferon and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to a subject an effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), and an inhibitor of cytochrome P450 (e.g., ritonavir). | 10-30-2014 |
20140349921 | HCV NS3 PROTEASE INHIBITORS - The present invention is directed to compounds, compositions and methods for treating or preventing HCV viral infections in human patients or other animal hosts. | 11-27-2014 |
20140357551 | ORGANIC COMPOUNDS AND THEIR USES - The present application describes organic compounds of Formula (II) | 12-04-2014 |
20140371137 | PREPARATION OF PNA-6-AMINOGLUCOSAMINE CONJUGATES AS ANTIVIRAL AGENTS - The present invention relates to methods and compositions pertaining to conjugates comprising a nucleic acid oligomer conjugated to a glucosamine or a derivative thereof which are useful for inhibiting the transcription of target nucleic acids. The conjugates of the invention exhibit advantageous bioavailability and readily penetrate cell membranes which make them useful for inhibiting translation of target mRNA in vivo. | 12-18-2014 |
20140371138 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION - The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. | 12-18-2014 |
20150024999 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. Preferably, the treatment is over a shorter duration, such as no more than 12 weeks. In one aspect, the therapies comprise administering at least two direct acting antiviral agents and ribavirin to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2 (or therapeutic agent 3), an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin. | 01-22-2015 |
20150025000 | Methods for Treating HCV - The present invention features interferon-free therapies for the treatment of HCV. The therapies comprise administering 2R,6S,13aS,14aR,16aS,Z)-N-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-exadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide (Compound I), or a pharmaceutically acceptable salt thereof, and another anti-HCV agent. Preferably, the therapies are both interferon- and ribavirin-free. The other anti-HCV agent can be a HCV polymerase inhibitor, an HCV NS5A inhibitor, an HCV entry inhibitor, a cyclophilin inhibitor, or an internal ribosome entry site inhibitor. Preferably, the other anti-HCV agent is an HCV polymerase inhibitor. Also preferably, the other anti-HCV agent is an HCV NS5A inhibitor. Also preferably, the other anti-HCV agent is administered concurrently with Compound I or a pharmaceutically acceptable salt thereof. In another example, the other anti-HCV agent is administered sequentially with Compound I or a pharmaceutically acceptable salt thereof. In still another embodiment, Compound I (or a pharmaceutically acceptable salt thereof) is co-administered with two or more other anti-HCV agents. For instance, Compound I (or a pharmaceutically acceptable salt thereof) can be co-administered with an HCV polymerase inhibitor and an HCV NS5A inhibitor. For another instance, Compound I (or a pharmaceutically acceptable salt thereof) can be co-administered with two different HCV polymerase inhibitors (e.g., one is a nucleoside polymerase inhibitor and the other is a non-nucleoside polymerase inhibitor; or both are nucleoside polymerase inhibitors; or both are non-nucleoside polymerase inhibitor). In yet another example, Compound I (or a pharmaceutically acceptable salt thereof) is co-administered with another HCV protease inhibitor and an HCV polymerase inhibitor. In still another example, Compound I (or a pharmaceutically acceptable salt thereof) is administered with two different HCV NS5A inhibitors. | 01-22-2015 |
20150031603 | MACROCYCLIC COMPOUNDS FOR SUPPRESSING REPLICATION OF HEPATITIS C VIRUS - A compound as represented by Formula (I) is provided, wherein groups are defined in the description. The compound is used as HCV protease inhibitor for treating HCV infection. | 01-29-2015 |
20150057218 | INHIBITORS OF HCV NS5A - Provided herein are compounds, pharmaceutical compositions and combination therapies for inhibition of hepatitis C. | 02-26-2015 |
20150119319 | MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS - The present invention relates to novel fluorinated macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient. | 04-30-2015 |
20150133368 | MACROCYCLIC AND PEPTIDOMIMETIC COMPOUNDS AS BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE PROTEASES OF PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES - Antiviral protease inhibitors, including macrocylic transition state inhibitors and peptidomimetics are disclosed, along with related antiviral compounds, and methods of using the same to treat or prevent viral infection and disease. The compounds possess broad-spectrum activity against viruses that belong to the picornavirus-like supercluster, which include important human and animal pathogens including noroviruses, sapoviruses, enteroviruses, poliovirus, foot-and-mouth disease virus, hepatitis A virus, human rhinovirus (cause of common cold), human coronavirus (another cause of common cold), transmissible gastroenteritis virus, murine hepatitis virus, feline infectious peritonitis virus, and severe acute respiratory syndrome coronavirus. | 05-14-2015 |
20150133369 | PHARMACOKINETIC MODULATION WITH ALISPORIVIR - A method of using alisporivir to therapeutically alter the pharmacokinetics of a medication whereby alisporivir has an effect that achieves and preserves similar safety and efficacy of said drugs with lower doses, less frequent administration, or both. | 05-14-2015 |
20150141326 | ANTIVIRAL COMPOUNDS - The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. | 05-21-2015 |
20150328280 | ALISPORIVR FOR TREATMENT OF HEPATITIS C VIRUS INFECTION - The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus infection. | 11-19-2015 |
20160067302 | Hepatitis C Virus Inhibitors - Hepatitis C virus inhibitors are disclosed having the general formula: | 03-10-2016 |
20160074462 | Method of Treating HCV - This application features methods of treating HCV using Compound 1/r, Compound 2 and/or Compound 3. | 03-17-2016 |
20160082069 | 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION - The invention provides pharmaceutical compositions comprising a compound of formula | 03-24-2016 |
20160108104 | APOLIPOPROTEIN E POLYPEPTIDES AND THEIR USE - Disclosed herein are several apoplipoprotein E (ApoE) polypeptides, and nucleic acids encoding these polypeptides, that can be used to treat or prevent a hepatitis infection in a subject, such as a hepatitis C virus infection. These ApoE polypeptides can inhibit the entry of hepatitis C virus into cells, and inhibit viral replication. Nucleic acids encoding these polypeptides are also disclosed, as well as methods | 04-21-2016 |
20160130307 | HEPATITIS B VIRUS PRE-S1 DERIVED SYNTHETIC POLYPEPTIDES AND USES THEREOF - The invention relates to a group of synthetic polypeptides, derived from the pre-S1 region of HBV, that efficiently interfere with early steps of an HBV infection. The peptides of the invention can be used in diagnostics for the detection of antigens and/or antibodies. | 05-12-2016 |
20160194352 | AMORPHOUS FORMS OF DACLATASVIR DIHYDROCHLORIDE | 07-07-2016 |